人血丙种球蛋白治疗小儿难治性肺炎支原体肺炎的临床分析

Clinical efficacy of blood gamma globulin treating refractory mycoplasma pneumoniae pneumonia

目的探讨人血丙种球蛋白治疗小儿难治性肺炎支原体肺炎的临床疗效。方法选取2012年3—12月在商丘市第一人民医院治疗的小儿难治性肺炎支原体肺炎64例，完全随机分为观察组和对照组，观察组32例患儿在常规抗感染、止咳化痰、吸氧、镇静、雾化吸入等治疗基础上给予人血丙种球蛋白治疗，对照组32例患儿仅给予常规治疗。结果观察组的治愈率为96.9%（31/32），对照组治愈率为81.2%（26/32），2组比较差异有统计学意义（P〈0.05）；观察组咳嗽缓解、体温恢复正常及住院时间明显短于对照组［（9.7±1.9）d比（12.4±2.2）d，（8.3±1.1）d比（11.2±1.0）d，（10.3±2.1）d比（12.2±2.4）d，P〈0.05］；观察组治疗后外周血T淋巴细胞亚群中CD3＋和CD4＋较治疗前明显升高，CD8＋明显降低，且明显优于对照组（P〈0.05） 。结论在疾病早期使用人血丙种球蛋白治疗小儿难治性肺炎支原体肺炎，可提高治疗效果，有利于疾病恢复。

ObjectiveTo investigate the clinicai effect of blood gamma globulin treating refractory mycoplasma pneumoniae pneumonia. MethodsA total of 64 patients with refractory mycoplasma pneumoniae pneumonia were enrolled from our hospital from March 2012 to December 2012, and they were randomly divided into observation group and control group; each group contained 32 cases. The two groups of patients were given antibiotics, cough and phlegm, oxygen,sedation, aerosol inhaiation and other conventional treatment. Observation group on the basis of the conventional treatment plus human blood gamma globulin treatment. ResultsAfter the treatment, the total cure rate of the observation group was 96.9%（31/32）. The differences were significant between the two groups（P〈0.05）. The time of cough relieve, temperature recover and length of stay of the observation group were significantly shorter than those of the control group[（9.7±1.9）d vs （12.4±2.2）d,（8.3±1.1）d vs （11.2±1.0）d,（10.3±2.1）d vs（12.2±2.4）d, P〈0.05]. There were significant differences of CD3＋ ,CD4＋ and CD8＋ between the two groups （P〈 0.05）. ConclusionBased on the conventional treatment, the use of blood gamma globulin in treatment of refractory mycoplasma pneumoniae pneumonia is good and worthy of clinical application.